CELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

Press/Media: Press / Media

PeriodAug 16 2019

Media coverage

6

Media coverage

  • TitleCELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletMarketScreener.com
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as Firs
    Media name/outletADVFN Deutschland
    CountryGermany
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC ® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletStockwatch
    CountryCanada
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC(R) (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletPredictWallStreet
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleCelgene Corp: U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis (Businesswire)
    Media name/outletAvanza Bank AB
    CountrySweden
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBICÂ Fedratinib as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date8/16/19
    PersonsRuben Mesa